High Purity Pharmaceutical Raw Material Cediranib / Azd2171 (288383-20-0)

Model NO.: 288383-20-0 Synonyms: Azd2171;Recentin;Cediranib R Appearance: White Crystalline Solid Trademark: shuangbojie Origin: China Name: Cediranib CAS: 288383-20-0 Assay: 99% Specification: ISO9001 HS Code: 29144000 Cediranib Synonyms:AZD2171;4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;Recentin;Cediranib R CAS:288383-20-0 MF:C25H27FN4O3 MW:450.51 Appearance: White crystalline solid Assay:99% Solubility:DMSO (10 mM) Storage Temp.: -20°C Shipping Conditions: RT Handling: Protect from air and moisture Description:Cediranib (AZD2171) s a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. Usage:Cediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively. Packing:1g/foil bag   Abstract Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration of AZD2171-an oral tyrosine kinase inhibitor of VEGF receptors-has rapid onset, is prolonged but reversible, and has the significant clinical benefit of alleviating edema. Reversal of normalization began by 28 days, though some features persisted for as long as four months. Basic FGF, SDF1alpha, and viable circulating endothelial cells (CECs) increased when tumors escaped treatment, and circulating progenitor cells (CPCs) increased when tumors progressed after drug interruption. Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor.

Application: Cediranib inhibition of bFGF and EGF when an IC50 of 0.5 and 0.11 μM. In the MG63 cell lines, Cediranib inhibiting PDGF-AA, IC50 of 0.04 μM. Cediranib Flt-1 associated kinase inhibition, IC50 of 5 nM, Cediranib inhibition of VEGF-C and VEGF-D receptor Flt-4, IC50 of less than 3 nM. [1] In addition, cediranib inhibition of c-Kit and PDGFR-β tyrosine kinase, IC50 were 2 and 5 nM. In vitro, micromolar concentrations cediranib can directly inhibit the proliferation of tumor cells. Sub nanomolar Cediranib blocking tubules produced, and inhibits VEGF-induced angiogenesis in vivo.  

Name	CAS NO.	Usage
AICAR	2627-69-2	acts by entering nucleoside pools, significantly increasing  levels of adenosine during periods of ATP breakdown
MK2866	841205-47-8	medical prescription for prevention of cachexia, atrophy,  and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677	15972-10-0	A growth hormone secretagogue, treatment of obesity,  a promising therapy for the treatment of frailty in the elderly
LGD-4033	1165910-22-4	pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516	317318-70-0	For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4)	401900-40-0	partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009	1379686-30-2	under development at The Scripps Research Institute (TSRI),  increases the level of metabolic activity in skeletal muscles of mice
RAD140	1182367-47-0	New generation for gaining mass and cutting edges
YK11	431579-34-9	YK11: a SARM and myostatin inhibitor in one

Our advantages:
1. High quality products with competitive prices
2. Professional service
3. Enough stock and Fast delivery
Terms of payment: T/T, Western Union, Money Gram
Way of shipping: EMS, DHL, FedEx, UPS
Delivery Time: Within 24 hours after payment
Packing: Discreet and tight safe packing for Customs pass guaranteed
We supply high quality products. Welcome for any inquiries

Contact us if you need more details on Cediranib. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Azd2171、Ligandrol. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Pharmaceutical Intermediates